E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Dementia is most often caused by Alzheimers disease which results in a decrease in cognitive functions and leads to ealier death |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To examine the effect of a 6 month treatment course with Victoza, a GLP-1 receptor agonist, on intracerebral amyloid aggregations determined by Pittsburgh Compound B PET-scans. |
|
E.2.2 | Secondary objectives of the trial |
To examine the effect of a 6 month treatment course with Victoza, a GLP-1 receptor agonist, on the clinical course of AD as determined by validated neuropsychological tests (MMSE and Addenbrookes cognitive evaluation test).
Secondary 2:
To examine the effect of a 6 month treatment course with Victoza, a GLP-1 receptor agonist, on FDG metabolism in the brain as determined by PET-scans
To examine the effect of a 6 month treatment course with Victoza, a GLP-1 receptor agonist, by MR scans. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients diagnosed with AD by MMSE score and/or spinal puncture (If MMSE score is between 18-21 the patient is diagnosed by clinical symptoms only. If the MMSE score is > 22 a spinal puncture will be performed to diagnose the patient)
Age ≥ 50 years and ≤ 80 years
|
|
E.4 | Principal exclusion criteria |
Diabetes mellitus
Liver or kidney insufficiency (alanine transferase levels more tha twice upper normal, plasma creatinine > 130µmol/l), clinical relevant anaemia
Current or earlier presence of another CNS disease (except for well-treated depression) or clinical relevant liver disease, kidney disease or endocrinological disease (except hypothyreoism).
Current or history of chronic or acute pancreatitis
If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable
Claustrophobia or other missing co-orporation
Severe overweight > 130kg
Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body
Significant abnormities in the brain detected by MR scanning
Known abuse of alcohol or drugs
Every disease or treatment that the head investigator considers to have a possible effect on results of the study
Allergy to the drugs or diagnosing procedure used in the study
Participation in a clinical study 3 months prior to inclusion in this study
Patients who have previously participated in investigations with isotopes or ionizing radiation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pittsburgh Compound B PET scanning will be used to examine the primary objective of the study.
Positron emission tomography (PET) scanning is an establisehed method for the demonstration of CNS changes caused by AD, including changes in deposits of amyloid. In AD patients, PET can be used to investigate changes in glucose metabolism, different neurotransmitter systems, neuroinflammation and protein deposits, amyloid deposits in particular. Amyloid beta accumulations are crucial patological findings in AD. Recently, amyloid tracers have been developed for PET which makes in vivo amyloid visualisation possible. It has been shown that the carbon-11 labelled Pittsburgh Compound B (PiB) PET tracer can be used to study amyloid deposits in living humans. PiB was among the first PET tracers to visualise amyloid and its effect is among the most well documented. Patients are not expected to experience any short- or long-term discomfort from the PET scans, apart from that assosiated to the insertion of cannulas.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary1:
To study the effect of a 6 month treatment course with liraglutide we will use validated neuropsychological tests (MMSE and Addenbrookes cognitive evaluation test) developed to characterization of disease progression in patients with AD.
Secondary2:
Moreover, we want to examine the effect of a 6 month treatment course with liraglutide, on FDG metabolism in the brain as determined 18F-flouro-2-deoxy-glucose PET-scans (FDG PET).
A recent study have demonstrated that the glucose-analog 18F-flouro-2-deoxy-glucose PET tracer can be used to monitor the progressive reduction in cerebral glucose metabolism in patients with AD before clinical symptoms appear.
Secondary3:
At the 1st and last visit a perfusion-weighted MR scan of the brain will be performed. The perfusion-weighted MR-scan is a supplying marker for the severity of Alzheimer’s disease and can improve the sensitivity of the study drug’s effect in the brain. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |